Citalopram for the Treatment of Adolescent Anxiety Disorders: A Pilot Study

Charts of 17 adolescent patients treated naturalistically with citalopram for various anxiety disorders were reviewed. Patients were retrospectively assessed using the Clinical Global Impression (CGI)-Severity scale at the beginning and end of treatment. Eighty-two percent (14/17) of patients were rated as much or very much improved on the CGI-Improvement scale after treatment with citalopram. Patients were treated for an average of 156-/+85.1 days at a mean dose of 32.3-/+18.5 mg/day of citalopram. Fifty-three percent (9/17) of this sample had previous exposure to alternative selective serotonin reuptake inhibitors, and 89% (8/9) of those patients responded positively to citalopram. Citalopram appeared well tolerated, with only one patient discontinuing treatment due to side effects. In this naturalistic setting, citalopram appeared to be a well-tolerated and effective treatment for a range of anxiety disorders in adolescents.

Authors

Institutions

Publication Details

Journal
Psychopharmacology Bulletin
Published
2025-08-12
DOI
https://doi.org/10.64719/pb.4217
Citations
5
Primary Topic
Attention Deficit Hyperactivity Disorder
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Citalopram for the Treatment of Adolescent Anxiety Disorders: A Pilot Study

Jeff Q. Bostic, Jefferson B. Prince, Michael C. Monuteaux, Suzanne Place et al.
5 citations
Psychopharmacology Bulletin
Attention Deficit Hyperactivity Disorder
article

Citalopram for the Treatment of Adolescent Anxiety Disorders: A Pilot Study

Jeff Q. Bostic, Jefferson B. Prince, Michael C. Monuteaux, Suzanne Place, Kenneth L. Brown
article en
5 citations

Abstract

Charts of 17 adolescent patients treated naturalistically with citalopram for various anxiety disorders were reviewed. Patients were retrospectively assessed using the Clinical Global Impression (CGI)-Severity scale at the beginning and end of treatment. Eighty-two percent (14/17) of patients were rated as much or very much improved on the CGI-Improvement scale after treatment with citalopram. Patients were treated for an average of 156-/+85.1 days at a mean dose of 32.3-/+18.5 mg/day of citalopram. Fifty-three percent (9/17) of this sample had previous exposure to alternative selective serotonin reuptake inhibitors, and 89% (8/9) of those patients responded positively to citalopram. Citalopram appeared well tolerated, with only one patient discontinuing treatment due to side effects. In this naturalistic setting, citalopram appeared to be a well-tolerated and effective treatment for a range of anxiety disorders in adolescents.

Psychopharmacology BulletinVol. 36(3)
Harvard University (US)
Good health and well-being
Openalex Percentile: Top 100%
Attention Deficit Hyperactivity Disorder
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Citalopram for the Treatment of Adolescent Anxiety Disorders: A Pilot Study — Jeff Q. Bostic, Jefferson B. Prince, et al. · Psychopharmacology Bulletin (2025) | TGRS Research Map | TGRS